Effect of an Advanced Notification Letter on Screening Colonoscopy Participation

NCT ID: NCT02188927

Last Updated: 2014-07-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

6800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participation in a primary screening colonoscopy programs remains low. Advanced notification letter has been shown to increase participation in colorectal cancer screening with fecal occult blood testing and to be cost effective compared to standard invitation. It is unknown whether advanced notification letter increases participation rate in primary colonoscopy screening program.

We hypothesize that an Advance Notification Letter will have significant influence on participation in screening colonoscopy, comparing to standard invitation procedure and will thus result in higher efficiency of the program.

This randomized controlled study aims to compare the participation rate in screening colonoscopy in response to advanced notification plus standard invitation letter and standard invitation letter alone.

Material and methods: 6800 individuals aged 55-64 years will be drawn from the Population Registry and randomly assigned in a 1:1 ratio to the group invited for screening colonoscopy with advanced notification letter (send two weeks before standard invitation) plus standard invitation (send six weeks before planned screening colonoscopy) or to standard invitation only (send six weeks before planned screening colonoscopy). The sample size was calculated to detect 3% difference in participation rate between the groups (25% vs 28%) with 80% power.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Adenoma Rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Implementation of ANL

Intervention: Procedure : Implementation of routine Advanced Notification Letter included in Standard Invitation procedure

Advanced Notification Letter will be implemented in invitation procedure and send two weeks before Standard Invitation (Standard Invitation will be send six weeks before planned screening colonoscopy)

Group Type EXPERIMENTAL

Implementation of ANL

Intervention Type OTHER

Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy

No included ANL

Intervention: Behavioral : No included Advanced Notification Letter Sending Standard Invitation six weeks before planned screening colonoscopy

Group Type ACTIVE_COMPARATOR

No included ANL

Intervention Type BEHAVIORAL

Sending Standard Invitation only six weeks before planned screening colonoscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implementation of ANL

Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy

Intervention Type OTHER

No included ANL

Sending Standard Invitation only six weeks before planned screening colonoscopy

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all individuals aged 55-64 years living in the counties covered with the organized CRC screening program and assigned to invitation to screening colonoscopy in the year 2014 are eligible for the study.

Exclusion Criteria

* message from neighbor/family/post office on death of screenee (not updated in Population Registry)
* resident abroad (not updated in Population Registry)
* return of unopened letter of invitation and/or reminder (address unknown)
* diagnosis of CRC before the date of draw (not updated in the National Cancer Registry)
Minimum Eligible Age

55 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre of Postgraduate Medical Education

OTHER

Sponsor Role collaborator

European Union

OTHER

Sponsor Role collaborator

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Karolina Janikowska, MD,MSc

Role: PRINCIPAL_INVESTIGATOR

The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Jaroslaw Regula, MD, PhD

Role: STUDY_CHAIR

The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Bartlomiej Kocot

Role: STUDY_DIRECTOR

The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Warsaw, Mazovian, Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Karolina Janikowska, MD, MSc

Role: primary

22 546 30 58 ext. +48

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TEAM/2012-9/5

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.